Ayman Noreddin

Dr Noreddin received his Ph.D. in Pharmaceutical Sciences from the University of the Pacific, California. He received his research training as a visiting scholar at the Department of Medicine, Stanford University. Dr Noreddin had postdoctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, the University of Manitoba, Canada followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). 

Dr Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.

After receiving his American Leaders Fellow training by the American Council for Pharmacy Education (ACPE), Dr Noreddin pursued leadership position as a Department Chair, Hampton University, VA then as an Associate Dean for Academic Affairs, Chapman University, CA. He moved to the UAE to serve as a Dean of Pharmacy, University of Sharjah. Currently he is the Dean of the Faculty of Pharmacy, Galala University, and the Global Academic Pharmacy Leader, FIP/WHO, Regional Office.

• Ph.D. in Pharmaceutical Sciences from the University of the Pacific, California.
• Postdoctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, the University of Manitoba, Canada.
• Postdoctoral fellowship in American College of Clinical Pharmacy (Infectious Diseases).

Pharmacokinetic/Pharmacodynamic modelling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies.

• Member of the Arab Scientific Board 2020.
• Nominated Global Academic Leader, WHO-EMRO PHARM, International Pharmacy Federation (FIP) 2019.
• Nominated member at the “Emirates Council of Scientists”, UAE, March 2018.
• Reviewer for the National Institute of Health (NIH), special session: “Drug Discovery and Mechanisms of Antimicrobial Resistance”, February 2017.
• Invited speaker at the1st ACU International Conference of Pharmaceutical Sciences On New Trends in Pharmaceutical and Medical Research, Giza, Egypt, May 2016.
• Invited speaker at the Faculty of Pharmacy, UNICAPM University, Campinas, Brazil, August 2016.
• Key Note Speaker at the 3rdInternational Conference on Clinical Pharmacy, Atlanta, Ca, December 2015.
• Invited speaker at the 3rd FUE International Conference of Pharmaceutical Sciences, Cairo, Egypt, Feb, 2005.
• Reviewer for the National Institute of Health (NIH), special session: “Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR)”, June 2015.
• Reviewer for the National Institute of Health (NIH), special session:” Pharmacological.
• Approached to Evaluating Drug Regimens to Address Antimicrobial Resistance”, January 2014.
• Member of the Organizing Committee, Plenary Speaker, International Summit on Clinical Pharmacy and Dispensing, San Antonio, TX, 2013.
• Member of Organizing Committee, Keynote Speaker and Chair, International Congress on Bacteriology and Infectious Diseases, Baltimore, 2013.
• Co-Chair, Infectious Diseases Session, International Conference on Clinical Microbiology and Microbial Genomics, San Antonio, TX, 2012.
• Session Chair, Clinical Trial-Part II, TM’s 2nd World Drug Discovery online conference.
• Member of the Editorial Board of the International Journal of Tumor Therapy, 2012.
• Board member, Egyptian Cancer Network 2011.
• Invited speaker: Meet-the-Professor Session, Infectious Diseases Society of America(IDSA) 49th Annual Meeting, 2011.
• Session Chair, Clinical Trial-Part II, TM’s 1st World Drug Discovery online conference, 2011.
• Member of the advisory council for Egypt Cancer Network, 2011.
• Member of the Scientific Board, IN-Tech-Open Access Publisher, 2011.
• Editor in Chief. InTech- Open Access Publisher, 2011.
• Member of the Editorial Board of the Journal of Drug Metabolism & Toxicology, 2011.
• Member of the Editorial Board of International Scholarly Research Network (ISRN) Pulmonology, 2011.
• Invited advisor to the Faculty of Pharmacy, Al-Fateh University, Tripoli, Libya, 2010.
• Member of the editorial board of the “Egyptian Journal of Pharmaceutical Sciences”, Cairo University, Cairo, Egypt, 2010.
• Reviewer for the National Institute of Health (NIH), 2009.
• Elected advisor. Multicultural Pharmacy Students Organization, University of Minnesota, Duluth, 2008.
• Advisor for the PharmD 2012 class, College of Pharmacy, University of Minnesota, Duluth, 2008.
• Member of the Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health &Human Services, 2008.
• American College of Clinical Pharmacy/Aventis Pharmacotherapy Research Fellowship (Infectious Diseases), 2002.
• Director of the continuing education and research committee – Saudi Pharmaceutical Society, 1996.
• Membership in the Rho Chi Pharmaceutical Honorary Society, CA, USA, 1986.
• Graduate Students Fellowship, School of Pharmacy, University of the Pacific, 1985.
• Graduate Students Representative, School of Pharmacy, University of the Pacific, 1985.

• Teacher of the Year, College of Pharmacy, Duluth, University of Minnesota, 2007-2008.
• Teacher of the Semester, College of Pharmacy, Duluth, University of Minnesota, Fall 2007.

• Principal Investigator: Targeting breast cancer by novel exosome-based formulations of Anastrozole. Collaborative grant. The University of Sharjah, (200,000ADH), 2018.
• Principle Investigator: A Novel Antibiofilm Formulation to Treat Combat-Related Wound Infections, W81XWH-17-JPC-2/MIDRP-ARA. ($ 2M), 2017.
• Co-investigator: Design of novel cationic, amphipathic cellulose-based Nano biomaterials from agricultural residues for Drug Delivery: Application in the Treatment of Multi-Drug Resistant Planktonic and/or Biofilm-Embedded Bacteria. Academy of Scientific Research and Technology. ($100 K), July 2016.
• Co-investigator: “Quorum Quenching Enzymes: New Trend in Antimicrobial treatment: JESOR program, Academy of Science Research and Technology, Egypt. 2015 ($60,000).
• Principal Investigator: “Providing Medication Management Services”, Senior Services of Southeastern Virginia, 2013 ($4,800).
• Principal investigator: “Innovative technologies to effectively treat multi-drug resistant and/or biofilm-embedded bacteria “, Innovative Surface Technologies, Inc. (ISurTec), National Institute of Health (NIH)/SBIR. Grant number: 1R43GM093398-01A1, 2010-2012 ($40,000).
• Co-investigator: “Collaborative Pilot Study: Evaluating the efficacy of the Drug Information Database System at Hampton University School of Pharmacy”, Hampton University Faculty Institute Grant, 2010($5,200).
• Co-Investigator: “Relationship of MIC and AUC/MIC to vancomycin efficacy for treatment of methicillin-resistant Staphylococcus aureus pneumonia”, Whiteside Clinical Research Institute, 2008-2009 ($14,500).
• Principal Investigator: “A dynamic model of bio-film infected Cystic Fibrosis lung epithelial cells”, Grant-In-AID of research, Artistry, and Scholarship (Category 6, University of Minnesota 2007-2009 ($29,200).
• Principal Investigator: “High throughput and in vitro modeling strategies vs. catheter biofilms in elderly patients with complicated urinary tract infections “, Society of Infectious Diseases Pharmacist, 2007-2008 ($15,000).
• Principal Investigator: “Target Attainment Potential Study of Fluoroquinolones versus Resistant Strains of Streptococcuc pneumoniae” Schering Plough, 2007-2008 ($24,000).
• Principal Investigator: “Pharmacodynamic Profiling of Moxifloxacin and Comparators versus Susceptible and Genetically Characterized resistant strains of Streptococcus pneumoniae. Monte Carlo Simulation Analysis”. Schering Plough, 2006-2007 ($39,100).
  Principal Investigator: “Study of the Pharmacodynamic Activity of the New Respiratory Quinolones against Ciprofloxacin Resistant Mutants of Streptococcus pneumoniae”, Grant-In-AID of Research, Artistry, and Scholarship (Category I), University of Minnesota2006-2008 ($28,000).
  Principal Investigator: “Liquid Chromatography-Mass Spectroscopy Instrument”, Grant-In-Aid Program (Category II), University of Minnesota, 2005 ($38,000).
• Recipient: “Establishment of Clinical Pharmacology Research Laboratory with LC-MS instrument as the major component of Drug Metabolites, hormones, and other sophisticated assays”.Shimadzu Equipment Grants for Research, Shimadzu Scientific Instruments. , 2005 ($51,000).
• Principal Investigator: “Assessment of Moxifloxacin ability to eradicate and prevent the development of Streptococcus pneumoniae resistance: Clinical simulation and Monte Carlo analysis”. Whiteside Institute for Clinical Research, St.Luke’s Hospital, 2005-2006 ($10.000).
• Principal Investigator: “Target Attainment Analysis for Gatifloxacin 400 Daily in Immunocompetent Elderly and Immunocompromised Patients Hospitalized with Community-Acquired Pneumonia”.
  Bristol Meyers Squibb, 2002-2003 ($12,000).
• Co-Investigator: “Simulation of Levofloxacin pharmacokinetics in patients with community-acquired pneumonia”.
  Ortho McNeil, 2001-2002 ($22,000).
• Co-investigator: “Pharmacokinetic/Pharmacodynamic modeling of various Nitrofurantoin formulations versus selected urinary tract isolates. “Procter and Gamble, 2000-2002 ($160.000).
• Co-investigator: “Pharmacodynamic modeling of Macrolides/ Ketolides against macrolide-resistant S.pneumoniae”. ABBOTT Laboratories, 2000-2001.